Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis
We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1537714/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319562888085504 |
|---|---|
| author | Yanjing Guo Yanjing Guo Jingjing Wu Qianming Bai Qianming Bai Juefeng Wan Juefeng Wan Juefeng Wan Qifeng Wang Qifeng Wang Xinhong He Xinhong He Xiaowei Zhang Xiaowei Zhang Zhiguo Luo Zhiguo Luo Liju Xing Xin Liu Xin Liu |
| author_facet | Yanjing Guo Yanjing Guo Jingjing Wu Qianming Bai Qianming Bai Juefeng Wan Juefeng Wan Juefeng Wan Qifeng Wang Qifeng Wang Xinhong He Xinhong He Xiaowei Zhang Xiaowei Zhang Zhiguo Luo Zhiguo Luo Liju Xing Xin Liu Xin Liu |
| author_sort | Yanjing Guo |
| collection | DOAJ |
| description | We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu). |
| format | Article |
| id | doaj-art-9b14c704a61a4ea4bbf68b4f108da37b |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-9b14c704a61a4ea4bbf68b4f108da37b2025-08-20T03:50:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.15377141537714Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosisYanjing Guo0Yanjing Guo1Jingjing Wu2Qianming Bai3Qianming Bai4Juefeng Wan5Juefeng Wan6Juefeng Wan7Qifeng Wang8Qifeng Wang9Xinhong He10Xinhong He11Xiaowei Zhang12Xiaowei Zhang13Zhiguo Luo14Zhiguo Luo15Liju Xing16Xin Liu17Xin Liu18Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Multidisciplinary Oncology, Fuzhou First General Hospital Affiliated with Fujian Medical University, Fujian, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaShanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Oncology, Jiangyin Traditional Chinese Medicine Hospital, Jiangyin, ChinaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaWe present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu).https://www.frontiersin.org/articles/10.3389/fonc.2025.1537714/fullaggressive fibromatosisEGFR 19deltargeted therapygefitinibpartial response |
| spellingShingle | Yanjing Guo Yanjing Guo Jingjing Wu Qianming Bai Qianming Bai Juefeng Wan Juefeng Wan Juefeng Wan Qifeng Wang Qifeng Wang Xinhong He Xinhong He Xiaowei Zhang Xiaowei Zhang Zhiguo Luo Zhiguo Luo Liju Xing Xin Liu Xin Liu Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis Frontiers in Oncology aggressive fibromatosis EGFR 19del targeted therapy gefitinib partial response |
| title | Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis |
| title_full | Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis |
| title_fullStr | Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis |
| title_full_unstemmed | Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis |
| title_short | Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis |
| title_sort | case report gefitinib in egfr 19del recurrent aggressive fibromatosis |
| topic | aggressive fibromatosis EGFR 19del targeted therapy gefitinib partial response |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1537714/full |
| work_keys_str_mv | AT yanjingguo casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT yanjingguo casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT jingjingwu casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT qianmingbai casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT qianmingbai casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT juefengwan casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT juefengwan casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT juefengwan casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT qifengwang casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT qifengwang casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT xinhonghe casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT xinhonghe casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT xiaoweizhang casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT xiaoweizhang casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT zhiguoluo casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT zhiguoluo casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT lijuxing casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT xinliu casereportgefitinibinegfr19delrecurrentaggressivefibromatosis AT xinliu casereportgefitinibinegfr19delrecurrentaggressivefibromatosis |